Patents by Inventor Shahriar Shane Taremi

Shahriar Shane Taremi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY
    Publication number: 20240002535
    Abstract: Arginase 1 binders that inhibit activity of hArg1, which comprise humanized anti-human Arginase 1 (hArg1) antibodies and antigen-binding fragments thereof obtained from mouse monoclonal antibodies comprising mouse VH and VL, are described. These Arginase 1 binders present an alternative mechanism for inhibiting hArg1 activity and highlight the ability to utilize binders as probes in the discovery and development of peptide and small molecule inhibitors for enzymes in general.
    Type: Application
    Filed: November 22, 2021
    Publication date: January 4, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Marc Andre Bailly, Kalyan Chakravarthy, Ghassan Najib Fayad, Laurence Fayadat-Dilman, Veronica Juan, Esther Kofman, Masahisa Handa, Jennifer E. O'Neil, Rachel Lynn Palte, Giovanna Scapin, Shahriar Shane Taremi
  • ARGINASE 1 BINDERS FOR INHIBITING ARGINASE 1 ACTIVITY
    Publication number: 20240002534
    Abstract: Arginase 1 binders that inhibit the activity of human Arginase 1 (hArg1) and comprise human antibodies and antigen-binding fragments thereof comprising human VH and VL are described. These Arginase 1 binders present an alternative mechanism for inhibiting hArg1 activity and highlight the ability to utilize binders as probes in the discovery and development of peptide and small molecule inhibitors for enzymes in general.
    Type: Application
    Filed: November 22, 2021
    Publication date: January 4, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Marc Andre Bailly, Kalyan Chakravarthy, Ghassan Najib Fayad, Laurence Fayadat-Dilman, Esther Kofman, Masahisa Handa, Jennifer E. O'Neil, Rachel Lynn Palte, Giovanna Scapin, Shahriar Shane Taremi
  • Crystal of pregnane X receptor fused to steroid receptor coactivator-1
    Patent number: 8048663
    Abstract: The present invention relates to Pregnane X receptor (PXR) polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: November 1, 2011
    Assignee: Schering Corp.
    Inventors: Wenyan Wang, Shahriar Shane Taremi, Winifred Prosise, Paul Reichert, Charles A. Lesburg, Vincent S. Madison, Kuo-Chi Cheng
  • Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides
    Patent number: 8034907
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: October 11, 2011
    Assignee: Schering Corp.
    Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
  • HDM2 polypeptides
    Patent number: 7888474
    Abstract: The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: February 15, 2011
    Assignee: Schering Corporation
    Inventors: Thomas E. Hesson, Hung V. Le, Yao Ma, Vincent S. Madison, Anthony F. Mannarino, Paul Reichert, Gerald W. Shipps, Jr., Corey O. Strickland, Shahriar Shane Taremi, Yaolin Wang, Rumin Zhang, Jose Duca
  • Pregnane X Receptor Compositions, Crystals and Uses Thereof
    Publication number: 20100286372
    Abstract: The present invention relates, inter alia, to PXR polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.
    Type: Application
    Filed: June 15, 2010
    Publication date: November 11, 2010
    Applicant: Schering Corporation
    Inventors: Wenyan Wang, Shahriar Shane Taremi, Winifred Prosise, Paul Reichert, Charles A. Lesburg, Vincent S. Madison, Kuo-Chi Cheng
  • HDM2 POLYPEPTIDES
    Publication number: 20100267150
    Abstract: The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.
    Type: Application
    Filed: March 12, 2010
    Publication date: October 21, 2010
    Inventors: THOMAS E. HESSON, HUNG V. LE, YAO MA, VINCENT S. MADISON, ANTHONY F. MANNARINO, PAUL REICHERT, GERALD W. SHIPPS, JR., COREY O. STRICKLAND, SHAHRIAR SHANE TAREMI, YAOLIN WANG, RUMIN ZHANG, JOSE DUCA
  • Pregnane X receptor compositions, crystals and uses thereof
    Patent number: 7785879
    Abstract: The present invention relates, inter alia, to PXR polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.
    Type: Grant
    Filed: September 18, 2006
    Date of Patent: August 31, 2010
    Assignee: Schering Corporation
    Inventors: Wenyan Wang, Shahriar Shane Taremi, Winifred W. Prosise, Paul Reichert, Charles A. Lesburg, Vincent S. Madison, Kuo-Chi Cheng
  • METHODS FOR CRYSTALLIZING ERK2 POLYPEPTIDES
    Publication number: 20100190231
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Application
    Filed: April 5, 2010
    Publication date: July 29, 2010
    Inventors: JESSIE M. ENGLISH, Thierry Oliver Fischmann, Thomas Hesson, Alan William Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Shane Taremi
  • SOLUBLE, STABLE FORM OF HDM2, CRYSTALLINE FORMS THEREOF AND METHODS OF USE THEREOF
    Publication number: 20100136620
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Application
    Filed: November 18, 2009
    Publication date: June 3, 2010
    Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
  • Methods for crystallizing ERK2 polypeptides
    Patent number: 7722718
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Grant
    Filed: October 17, 2007
    Date of Patent: May 25, 2010
    Assignee: Schering Corporation
    Inventors: Jessie English, Thierry Oliver Fischmann, Thomas Hesson, Alan William Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Shane Taremi
  • HDM2 Polypeptides
    Patent number: 7705127
    Abstract: The present invention relates to HDM2 polypeptides and mutants thereof which are complexed with various compounds, e.g., HDM2 inhibitors.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: April 27, 2010
    Assignee: Schering Corporation
    Inventors: Thomas E. Hesson, Hung V. Le, Yao Ma, Vincent S. Madison, Anthony F. Mannarino, Paul Reichert, Gerald W. Shipps, Jr., Corey O. Strickland, Shahriar Shane Taremi, Yaolin Wang, Rumin Zhang, Jose Duca
  • Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
    Patent number: 7632920
    Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: December 15, 2009
    Assignee: Schering Corporation
    Inventors: Shahriar Shane Taremi, Gaolian Xie, Thomas Hesson, Jose S. Duca, Corey Strickland, William T. Windsor, Vincent S. Madison, Rumin Zhang, Paul Reichert, Yaolin Wang
  • CATALYTIC DOMAIN OF ADAM33 AND METHODS OF USE THEREOF
    Publication number: 20080199447
    Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.
    Type: Application
    Filed: December 20, 2007
    Publication date: August 21, 2008
    Inventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
  • Catalytic domain of ADAM33 and methods of use thereof
    Patent number: 7335758
    Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: February 26, 2008
    Assignee: Schering Corporation
    Inventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
  • ERK2 crystals
    Patent number: 7312061
    Abstract: The present invention relates to crystals of the ERK2 polypeptide and complexes thereof which are useful, inter alia, for structure assisted drug design.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: December 25, 2007
    Assignee: Schering Corporation
    Inventors: Jessie English, Thierry Oliver Fischmann, Thomas Hesson, Alan William Hruza, Weihong Jin, Paul Reichert, Catherine Smith, Shahriar Shane Taremi
  • Catalytic domain of ADAM33 and methods of use thereof
    Patent number: 7208311
    Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: April 24, 2007
    Assignee: Schering Corporation
    Inventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
  • Catalytic domain of ADAM33 and methods of use thereof
    Publication number: 20040151715
    Abstract: The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.
    Type: Application
    Filed: December 19, 2003
    Publication date: August 5, 2004
    Applicant: Schering Corporation
    Inventors: Wenyan Wang, Hung V. Le, Jian-Jun Liu, Vincent S. Madison, Winifred W. Prosise, Shahriar Shane Taremi, Li Xiao, Jun Zou
  • Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
    Patent number: 6524589
    Abstract: The invention relates to the purification and crystallization of hepatitis C virus (HCV) NS3/NS4A polypeptide complex. Also, crystallization conditions for NS3/NS4A are provided. Further, the atomic coordinates for the NS3/NS4A protein are disclosed. Examples of its use for the determination of the three-dimensional atomic structures of HCV NS3/NS4A with substrate(s) or substrate analog(s) or inhibitor complexes are also provided.
    Type: Grant
    Filed: April 5, 2000
    Date of Patent: February 25, 2003
    Assignee: Schering Corporation
    Inventors: Paul Reichert, Winifred W. Prosise, Shahriar Shane Taremi, Nanhua Yao, Patricia C. Weber
  • Surface plasmon resonance based enzymatic assay
    Patent number: 5981167
    Abstract: A method for determining if an enzyme can cleave a substrate or if a substance is an inhibitor of the enzyme using surface plamon resonance.
    Type: Grant
    Filed: February 10, 1998
    Date of Patent: November 9, 1999
    Inventors: Shahriar Shane Taremi, Winifred W. Prosise